Fulltext
The Full text is available in PDF.
International Journal of Cancer Management
The Official Journal of Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences
e-ISSN 2538-497X
p-ISSN 2538-4422
The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine
Authors
Seyyed-Hossein Yahyazadeh-Jabbari1, Nasser Malekpour2, Bahram Salmanian3,*, Hossein Foodazi4, Masoud Salehi5, Farsad Noorizadeh2
1Clinical Research Center, Milad Hospital; Dept. of Radiation Oncology, Fayazbakhsh Hospital, Tehran, Iran
2Clinical Research Center, Milad Hospital, Tehran, Iran
3Clinical Research Center, Milad Hospital; Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4Dept. of Radiation Oncology, Fayazbakhsh Hospital, Tehran, Iran
5Clinical Research Center, Milad Hospital; Dept. of Statistics and Mathematics, School of Health Management and Information Sciences, Tehran University of Medical Sciences, Tehran, Iran
*Corresponding Author: Corresponding author: Bahram Salmanian, Clinical Research Center, Milad Hospital; Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran, Tel: +98-2188214139, E-mail: Email: [email protected]
Published online:Sep 30, 2013
Article type:Research Article
Received:Apr 09, 2013
Accepted:May 14, 2013
How to Cite:Yahyazadeh-Jabbari S, Malekpour N, Salmanian B, Foodazi H, Salehi M, et al. The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine. Int J Cancer Manag. 2013;6(3):e80420. doi:
Abstract
Background: Early stage gastric cancer diagnosis has ensued different approaches in resection strategies. In order to increase the proportion of cases which have undergone radical resection or have reduced the recurrence rate, different preoperative treatments have introduced. Here, we have verified an active preoperative chemotherapeutic regimen in locally advanced gastric cancer patients.
Methods: Forty nine patients who have found eligible to enter this phase 2 trial have treated with oxaliplatin 100 mg/m2 IV, docetaxel 50 mg/m2 IV, plus capecitabine 625 mg/m2 PO (TOX). Clinical staging has been following the first 2 cycles of induction chemotherapy. Patients that have further undergone radical surgery, have evaluated for pathological response rate.
Results: Anemia (10.2%), nausea (10.2%) and vomiting (6.1%) were the most frequent grade 3 or 4 adverse effects. Regarding the pathologic staging, 6 patients (12.2%) had complete response (95% CI 3% to 21.4%), 18 of them (36.7%) had partial response (95% CI 23.2% to 50.2%), then 3 patients (6.1%) had stable disease (95% CI 0%-12.8%). Among the patients who had surgery, 22% had pathologic complete response.
Conclusion: Preoperative chemotherapeutic regimen of TOX seems to be an active and safe neoadjuvant therapy in non metastatic gastric cancer. It should further be considered with concurrent radiotherapy.
Copyright
© 2013, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
30
Dec
2024
Pilot Study Comparing Epirubicin, Oxaliplatin, Capecitabine (EOX) and Docetaxel, Cisplatin, and 5-Fluorouracil (TCF) Regimens in Neoadjuvant Chemotherapy for Gastric Cancer Patients
Mehdi Cheraghi,
Ensiyeh Bahadoran,
Maryam Masoomi,
Navid Mohammadi
Cheraghi M, Bahadoran E, Masoomi M, Mohammadi N. Pilot Study Comparing Epirubicin, Oxaliplatin, Capecitabine (EOX) and Docetaxel, Cisplatin, and 5-Fluorouracil (TCF) Regimens in Neoadjuvant Chemotherapy for Gastric Cancer Patients. J Inflamm Dis. 2024;28(4):e154396. doi: https://doi.org/10.69107/jid-154396
13
May
2024
Pathologic Response Rates in Patients with Gastric Cancer Following FLOT Neoadjuvant Chemotherapy
Samaneh Sajjadi,
Mostafa Kamandi,
Abolghasem Allahyari,
Sajjad Ataei Azimi,
Alireza Baari,
Niloufar Valizadeh
,et al.Sajjadi S, Kamandi M, Allahyari A, Ataei Azimi S, Baari A, et al. Pathologic Response Rates in Patients with Gastric Cancer Following FLOT Neoadjuvant Chemotherapy. Int J Cancer Manag. 2024;17(1):e139026. doi: https://doi.org/10.5812/ijcm-139026
30
May
2017
Evaluation of Tumor Resectability Rate and Pathologic Response to Preoperative Concurrent Chemoradiotherapy in Locally Advanced Proximal Gastric and Esophagogastric Junction Adenocarcinomas: A Clinical Trial
Seyed Amir Aledavood,
Soodabe Shahid Sales,
Kazem Anvari,
Mohammad Naser Forghani,
Bahram Memar,
Ali Emadi Torghabeh
Aledavood SA, Shahid Sales S, Anvari K, Forghani MN, Memar B, et al. Evaluation of Tumor Resectability Rate and Pathologic Response to Preoperative Concurrent Chemoradiotherapy in Locally Advanced Proximal Gastric and Esophagogastric Junction Adenocarcinomas: A Clinical Trial. Int J Cancer Manag. 2017;10(5):e7473. doi: https://doi.org/10.5812/ijcm.7473
17
Jun
2019
Evaluation of Survival Rate and Non-Fetal Outcomes in Patients with Esophageal Cancer Under Treatment with Neoadjuvant Chemoradiotherapy Plus Additional Platinium-Based Chemotherapy from 2010 to 2016
Hasan Ali Vahedian,
Mohsen Akhondi-Meybodi,
Fatemeh Mansouri,
Masoud Shabani
Vahedian HA, Akhondi-Meybodi M, Mansouri F, Shabani M. Evaluation of Survival Rate and Non-Fetal Outcomes in Patients with Esophageal Cancer Under Treatment with Neoadjuvant Chemoradiotherapy Plus Additional Platinium-Based Chemotherapy from 2010 to 2016. Int J Cancer Manag. 2019;12(6):e89003. doi: https://doi.org/10.5812/ijcm.89003
30
Apr
2019
Comparison the Incidence and Severity of Side Effects Profile Of FOLFOX and DCF Regimens in Gastric Cancer Patients
Ebrahim Salehifar,
Razieh Avan,
Ghasem Janbabaei,
Seyed Khalil Mousavi,
Fatemeh Faramarzi
Salehifar E, Avan R, Janbabaei G, Mousavi SK, Faramarzi F. Comparison the Incidence and Severity of Side Effects Profile Of FOLFOX and DCF Regimens in Gastric Cancer Patients. Iran J Pharm Res. 2019;18(2):e126242. doi: https://doi.org/10.22037/ijpr.2019.1100663
Cited by
- Scopus by DOI: 0
Last Update: 3 weeks ago
- Scopus by Title: 0
Last Update: 3 weeks ago
- Scopus by Title (Ref): 2
Last Update: 3 weeks ago
- CrossRef: 0
Last Update: 1 day ago
Comments
Number of Comments:0